| 1 |
Ritchie AI, Wedzicha JA. Definition, causes, pathogenesis, and consequences of chronic obstructive pulmonary disease exacerbations[J]. Clin Chest Med, 2020, 41(3): 421-438.
|
| 2 |
Christenson SA, Smith BM, Bafadhel M, et al. Chronic obstructive pulmonary disease[J]. Lancet, 2022, 399(10342): 2227-2242.
|
| 3 |
陈海明，张贤春，齐见旭. 肌管蛋白相关蛋白14介导的线粒体自噬在慢性阻塞性肺疾病气道炎症中的作用研究[J]. 实用医学杂志，2022, 38(22): 2780-2786.
|
| 4 |
Xia Z, Wang Y, Liu F, et al. Association between TNF-α-308, ＋489, -238 polymorphism, and COPD susceptibility: An updated Meta-analysis and trial sequential analysis[J]. Front Genet, 2022, 2(3): 772032.
|
| 5 |
Shyam Prasad SB, Chaya SK, Kumar VS, et al. Inflammatory biomarkers interleukin 1 Beta (IL-1β) and tumour necrosis factor Alpha (TNF-α) are differentially elevated in tobacco smoke associated COPD and biomass smoke associated COPD[J]. Toxics, 2021, 9(4): 72.
|
| 6 |
宋素莉，贺英华，陈丽娟. COPD并发吸入性CAP危险因素及病原菌分析[J/CD]. 中华肺部疾病杂志(电子版), 2024, 17(2): 264-267.
|
| 7 |
Cazzola M, Page CP, Wedzicha JA, et al. Use of thiols and implications for the use of inhaled corticosteroids in the presence of oxidative stress in COPD[J]. Respir Res, 2023, 24(1): 194.
|
| 8 |
Chen H, Deng ZX, Sun J, et al. Association of inhaled corticosteroids with all-cause mortality risk in patients with COPD: a Meta-analysis of 60 randomized controlled trials[J]. Chest, 2023, 163(1): 100-114.
|
| 9 |
Yang M, Li Y, Jiang Y, et al. Combination therapy with long-acting bronchodilators and the risk of major adverse cardiovascular events in patients with COPD: a systematic review and meta-analysis[J]. Eur Respir J, 2023, 61(2): 2200302.
|
| 10 |
Fukuda N, Horita N, Kaneko A, et al. Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease[J]. Cochrane Database Syst Rev, 2023, 6(6): CD012066.
|
| 11 |
Fu Y, Chapman EJ, Boland AC, et al. Evidence-based management approaches for patients with severe chronic obstructive pulmonary disease (COPD): a practice review[J]. Palliat Med, 2022, 36(5): 770-782.
|
| 12 |
Martinez FJ, Rabe KF, Ferguson GT, et al. Reduced all-cause mortality in the ETHOS trial of Budesonide/Glycopyrrolate/Formoterol for chronic obstructive pulmonary disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study[J]. Am J Respir Crit Care Med, 2021, 203(5): 553-564.
|
| 13 |
Skolnik NS, Nguyen TS, Shrestha A, et al. Current evidence for COPD management with dual long-acting muscarinic antagonist/long-acting β2-agonist bronchodilators[J]. Postgrad Med, 2020, 132(2): 198-205.
|
| 14 |
Van Geffen WH, Tan DJ, Walters JA, et al. Inhaled corticosteroids with combination inhaled long-acting beta 2-agonists and long-acting muscarinic antagonists for chronic obstructive pulmonary disease[J]. Cochrane Database Syst Rev, 2023, 12(12): CD011600.
|
| 15 |
Burkes RM, Panos RJ. Ultra long-acting β-agonists in chronic obstructive pulmonary disease[J]. J Exp Pharmacol, 2020, 12: 589-602.
|
| 16 |
Lee SY, Lee JS, Lee SW, et al. Effects of treatment with long-acting muscarinic antagonists (LAMA) and long-acting beta-agonists (LABA) on lung function improvement in patients with bronchiectasis: an observational study[J]. J Thorac Dis, 2021, 13(1): 169-177.
|
| 17 |
Ariel A, Barnes PJ, Maricoto T, et al. Rational use of inhaled corticosteroids for the treatment of COPD: a plain language summary[J]. J Comp Eff Res, 2023, 12(12): e230136.
|
| 18 |
Adcock IM, Bhatt SP, Balkissoon R, et al. The use of inhaled corticosteroids for patients with COPD who continue to smoke cigarettes: an evaluation of current practice[J]. Am J Med, 2022, 135(3): 302-312.
|
| 19 |
Calzetta L, Ritondo BL, De Marco P, et al. Evaluating triple ICS/LABA/LAMA therapies for COPD patients: a network meta-analysis of ETHOS, KRONOS, IMPACT, and TRILOGY studies[J]. Expert Rev Respir Med, 2021, 15(1): 143-152.
|
| 20 |
Rogliani P, Cavalli F, Chetta A, et al. Potential drawbacks of ICS/LABA/LAMA triple fixed-dose combination therapy in the treatment of asthma: a quantitative synthesis of safety profile[J]. J Asthma Allergy, 2022, 15: 565-577.
|
| 21 |
Suissa S, Dell'Aniello S, Ernst P. Comparative effects of LAMA-LABA-ICS vs LAMA-LABA for COPD: Cohort study in real-world clinical practice[J]. Chest, 2020, 157(4): 846-855.
|
| 22 |
Gong Y, Sui Z, Lv Y, et al. LABA/LAMA versus LABA/ICS fixed-dose combinations in the prevention of COPD exacerbations: a modeling analysis of literature aggregate data[J]. Eur J Clin Pharmacol, 2023, 79(10): 1321-1332.
|
| 23 |
Brusselle G, Himpe U, Fievez P, et al. Evolving to a single inhaler extrafine LABA/LAMA/ICS-Inhalation technique and adherence at the heart of COPD patient care (TRIVOLVE)[J]. Respir Med, 2023, 218(1): 107368.
|
| 24 |
Monteagudo M, Nuñez A, Barrecheguren M, et al. Effectiveness of treatment with dual bronchodilation (LABA/LAMA) compared with combination therapy (LABA/ICS) for patients with COPD: a population-based study[J]. Arch Bronconeumol, 2022, 58(10): 699-707.
|
| 25 |
Buhl R, Dreher M, Mattiucci-Guehlke M, et al. EVELUT: A real-world, observational study assessing dyspnoea and symptom burden in COPD patients switched from LABA/ICS to LAMA/LABA or LAMA/LABA/ICS[J]. Adv Ther, 2023, 40(7): 3263-3278.
|
| 26 |
Lee YJ, Rhee CK, Hwang YI, et al. Escalation time to open triple combination therapy from the initiation of LAMA versus ICS/LABA in COPD management: Findings from comparing the incidence of tiotropium and ICS/LABA in real-world use in South Korea (CITRUS) study[J]. J Pers Med, 2021, 11(12): 1325.
|
| 27 |
Ferguson GT, Darken P, Ballal S, et al. Efficacy of Budesonide/Glycopyrronium/Formoterol fumarate metered dose inhaler (BGF MDI) versus other inhaled corticosteroid/long-acting muscarinic antagonist/long-acting β2-agonist (ICS/LAMA/LABA) triple combinations in COPD: a systematic literature review and network Meta-analysis[J]. Adv Ther, 2020, 37(6): 2956-2975.
|
| 28 |
Koarai A, Yamada M, Ichikawa T, et al. Triple versus LAMA/LABA combination therapy for Japanese patients with COPD: a systematic review and meta-analysis[J]. Respir Investig, 2022, 60(1): 90-98.
|
| 29 |
Choi KY, Kim HI, Rhee CK, et al. Comparing costs and healthcare resource utilization (HCRU) using LAMA versus LABA/ICS at treatment initiation for COPD: Findings from CITRUS (Comparing the Incidence of Tiotropium and ICS/LABA in Real-World Use in South Korea) Study[J]. Int J Chron Obstruct Pulmon Dis, 2024, 19(1): 1661-1671.
|
| 30 |
Chen CY, Pan SW, Hsu CC, et al. Comparative cardiovascular safety of LABA/LAMA FDC versus LABA/ICS FDC in patients with chronic obstructive pulmonary disease: a population-based cohort study with a target trial emulation framework[J]. Respir Res, 2023, 24(1): 239.
|